Retrospective review of patients with lentigo maligna treated with topical imiquimod 5% (Aldara®) at a single tertiary UK centre: need for more practical standardised treatment guidelines in the UK

Clin Exp Dermatol. 2024 Jan 25;49(2):163-165. doi: 10.1093/ced/llad332.

Authors

Usamah M Afzal¹, Sina J Ghadiri¹, Pavan Sambi¹, Andrew Muinonen-Martin¹, Angana Mitra¹

Affiliation

¹ Department of Dermatology, Leeds Teaching Hospitals NHS Trust, Leeds, UK.

PMID: 37758510
DOI: 10.1093/ced/llad332

No abstract available

MeSH terms

Administration, Topical
Aminoquinolines / adverse effects
Antineoplastic Agents* / therapeutic use
Humans
Hutchinson's Melanotic Freckle* / drug therapy
Imiquimod / therapeutic use
Retrospective Studies
Skin Neoplasms* / chemically induced
Skin Neoplasms* / drug therapy
United Kingdom

Substances

Imiquimod
Antineoplastic Agents
Aminoquinolines